Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China

Core Insights - Sisram Medical Ltd has achieved a significant milestone with its long-acting botulinum toxin type A product, DAXXIFY, passing quality testing from the National Institutes for Food and Drug Control of China, confirming its compliance with national drug regulatory standards [1][2] Product Overview - DAXXIFY is the world's first long-acting peptide-formulated neuromodulator, utilizing proprietary Peptide Exchange Technology (PXT) and a stabilized peptide formulation, designed for the temporary improvement of moderate to severe glabellar lines in adults [2] - The product has received initial commercial orders from several core medical aesthetic institutions, indicating strong market validation and recognition [2] Commercialization Strategy - The company has established a professional team focused on market expansion, clinical support, and supply chain management, enhancing its operational capabilities [3] - Strategic collaborations with industry leaders, such as Fosun Wanbang and Shanghai Pharmaceuticals, have been formed to ensure a reliable and compliant supply chain [3] Market Positioning - DAXXIFY is positioned as a premium injectable product in mainland China, expected to drive business growth and support Sisram's strategic expansion into injectables [4] - The product is anticipated to create a "second growth curve" for the company, reinforcing its competitiveness within an integrated wellness ecosystem [4] Company Background - Sisram Medical Ltd is a global leader in medical aesthetic solutions with over 25 years of experience in Energy-Based Devices, serving customers in over 110 countries [5] - The company is majority-owned by Fosun Pharma and has been listed on the Hong Kong Stock Exchange since September 2017 [5]